Factor VII or VIIA-like molecules
AssigneeBayer Health Care LLC
InventorsAnders Hjelholt Pedersen, Kim Vilbour Andersen, Claes Bornaes
Life of this patent
Estimating the term…
Abstract
Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
Claims25
A conjugate having clotting activity comprising:
- a recombinant polypeptide comprising an amino acid sequence which differs from the sequence shown in SEQ ID NO:1 in no more than 12 amino acid residues and in that the proline residue in position 10 and the lysine residue in position 32 of SEQ ID NO:1 are each substituted with an amino acid residue and an N-glycosylation site is introduced by the substitution of the valine residue in position 253 of SEQ ID NO:1 with an asparagine residue, wherein amino acid residue positions in the amino acid sequence of said polypeptide are numbered according to SEQ ID NO:1;
- and
- a sugar moiety covalently attached to the introduced N-glycosylation site.
A recombinant polypeptide having clotting activity comprising an amino acid sequence which differs from the sequence shown in SEQ ID NO:1 in no more than 12 amino acid residues and in that the proline residue in position 10 is substituted for an asparagine residue and the lysine residue in position 32 is substituted for a glutamic acid residue and an N-glycosylation site is introduced by the substitution of the valine residue in position 253 with an asparagine residue, wherein amino acid residue positions in said amino acid sequence of the polypeptide are numbered according to SEQ ID NO:1.
Dependencies are inferred from the claim text.